Table 1 Patients' characteristics at the time of primary diagnosis of breast cancer and correlations of the serum RNA and miR values with these parameters
From: Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
Parameters | Patients (%) | Total RNA | miR10b | miR34a | miR141 | miR155 |
|---|---|---|---|---|---|---|
Total | 89 | Median ± Standard Deviation | ||||
Age | 56 years | |||||
(range 31 - 82 years) | ||||||
Distant metastasis | ||||||
£ M0 | 59 | a 5.4 ± 3.5 | b 0.1 ± 0.2 | c 0.4 ± 0.6 | 0.00 ± 16.1 | d 2.4 ± 1.6 |
$ M1 | 30 | a 2.6 ± 1.5 | b 0.4 ± 0.6 | c 1.8 ± 2.7 | 0.0 ± 0.3 | d 1.5 ± 0.9 |
# Tumor stage | ||||||
pT1-2 | 27 (45.8) | e 3.6 ± 3.4 | 0.2 ± 0.2 | f 0.2 ± 0.6 | 0.0 ± 0.0 | 2.2 ± 1.9 |
pT3-4 | 32 (54.2) | e 7.3 ± 2.9 | 0.1 ± 0.1 | f 0.6 ± 0.5 | 0.0 ± 0.0 | 3.1 ± 1.3 |
# Lymph node metastasis | ||||||
N0 | 21 (35.6) | 7.3 ± 5.0 | 0.3 ± 0.2 | 0.6 ± 0.4 | 0.0 ± 0.01 | 2.2 ± 1 |
N1-3 | 38 (64.4) | 5.3 ± 2.1 | 0.1 ± 0.2 | 0.3 ± 0.7 | 0.0 ± 0.01 | 2.6 ± 1.9 |
# Grading | ||||||
II | 26 (44.1) | 3.4 ± 2.7 | 0.1 ± 0.3 | 0.3 ± 0.2 | 0.0 ± 0.02 | 1.6 ± 1 |
III | 33 (55.9) | 5.5 ± 3.8 | 0.1 ± 0.2 | 0.5 ± 0.7 | 0.0 ± 0.05 | 2.9 ± 1.7 |
# Estrogen receptor status | ||||||
positive | 37 (62.7) | 5.0 ± 3.3 | 0.1 ± 0.3 | 0.3 ± 0.3 | 0.0 ± 0.01 | 2.1 ± 1.2 |
negative | 22 (37.3) | 5.4 ± 4.4 | 0.2 ± 0.2 | 0.4 ± 0.7 | 0.0 ± 0.1 | 2.9 ± 1.8 |
# Progesterone receptor status | ||||||
positive | 33 (55.9) | 5.0 ± 3.1 | 0.1 ± 0.3 | 0.3 ± 0.2 | 0.0 ± 0.05 | 2.1 ± 1.1 |
negative | 26 (44.1) | 5.4 ± 3.9 | 0.1 ± 0.2 | 0.4 ± 0.7 | 0.0 ± 0.02 | 2.9 ± 1.8 |
# HER2 | ||||||
positive | 30 (53.6) | 3.9 ± 2.3 | 0.2 ± 0.3 | 0.3 ± 0.6 | 0.0 ± 0.01 | 2.4 ± 1.9 |
negative | 26 (46.4) | 6.0 ± 4.4 | 0.1 ± 0.2 | 0.6 ± 0.5 | 0.0 ± 0.1 | 2.9 ± 1.3 |
Number of CTC ¥ | ||||||
positive | 47 (82.5) | 2.9 ± 5.6 | 0.3 ± 0.3 | 0.5 ± 0.6 | 0.0 ± 0.0 | 2.2 ± 0.9 |
negative | 10 (17.5) | 5.5 ± 2.9 | 0.1 ± 0.2 | 0.3 ± 0.4 | 0.0 ± 0.0 | 2.5 ± 1.7 |